Baijin Life Science Holdings Limited (HKG:1466)
Hong Kong
· Delayed Price · Currency is HKD 0.520
-0.030 (-5.45%)
Mar 10, 2026, 10:41 AM HKT
HKG:1466 Income Statement
Financials in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 119.8 | 135.56 | 53.68 | 86.88 | 62.65 | 43.32 | Upgrade
|
| Revenue Growth (YoY) | 20.46% | 152.54% | -38.22% | 38.68% | 44.60% | -61.31% | Upgrade
|
| Cost of Revenue | 86.14 | 93.57 | 35.58 | 79.05 | 51.66 | 51.95 | Upgrade
|
| Gross Profit | 33.67 | 41.99 | 18.1 | 7.83 | 10.99 | -8.62 | Upgrade
|
| Selling, General & Admin | 35.99 | 37.32 | 28.56 | 16.62 | 15.61 | 21.25 | Upgrade
|
| Other Operating Expenses | -5.49 | -7.82 | -0.48 | -1.24 | 0.14 | -0.51 | Upgrade
|
| Operating Expenses | 28.64 | 27.94 | 27.68 | 10.5 | 11.22 | 33.64 | Upgrade
|
| Operating Income | 5.03 | 14.05 | -9.58 | -2.67 | -0.23 | -42.27 | Upgrade
|
| Interest Expense | -0.78 | -0.97 | -0.28 | -1.03 | -4.38 | -4.45 | Upgrade
|
| Interest & Investment Income | 1.31 | 1.6 | 1.32 | 0.22 | 0.01 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.06 | 0 | -2.98 | -1.11 | 6.33 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.88 | - | - | 14.91 | -10.26 | -0.29 | Upgrade
|
| EBT Excluding Unusual Items | 16.43 | 14.62 | -8.53 | 8.45 | -15.97 | -40.66 | Upgrade
|
| Impairment of Goodwill | -20 | -20 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -4.71 | Upgrade
|
| Gain (Loss) on Sale of Assets | 4.05 | 4.05 | - | - | 0.51 | 0.16 | Upgrade
|
| Asset Writedown | -0.03 | -0.03 | - | - | -0 | -1.27 | Upgrade
|
| Other Unusual Items | - | - | - | 0.23 | - | -5.59 | Upgrade
|
| Pretax Income | 0.45 | -1.37 | -8.53 | 8.68 | -15.46 | -52.08 | Upgrade
|
| Income Tax Expense | -3.88 | -1.28 | 0.02 | - | - | -0.29 | Upgrade
|
| Earnings From Continuing Operations | 4.33 | -0.09 | -8.55 | 8.68 | -15.46 | -51.79 | Upgrade
|
| Minority Interest in Earnings | 3.75 | -0.23 | 1.1 | - | - | - | Upgrade
|
| Net Income | 8.08 | -0.32 | -7.45 | 8.68 | -15.46 | -51.79 | Upgrade
|
| Net Income to Common | 8.08 | -0.32 | -7.45 | 8.68 | -15.46 | -51.79 | Upgrade
|
| Shares Outstanding (Basic) | 740 | 694 | 645 | 603 | 355 | 224 | Upgrade
|
| Shares Outstanding (Diluted) | 807 | 694 | 645 | 603 | 355 | 224 | Upgrade
|
| Shares Change (YoY) | 21.34% | 7.58% | 6.89% | 70.17% | 58.07% | 23.64% | Upgrade
|
| EPS (Basic) | 0.01 | -0.00 | -0.01 | 0.01 | -0.04 | -0.23 | Upgrade
|
| EPS (Diluted) | 0.01 | -0.00 | -0.01 | 0.01 | -0.04 | -0.23 | Upgrade
|
| Free Cash Flow | -20.63 | -32.97 | -6.64 | -21.55 | 1.06 | -16.21 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.05 | -0.01 | -0.04 | 0.00 | -0.07 | Upgrade
|
| Gross Margin | 28.10% | 30.97% | 33.72% | 9.01% | 17.55% | -19.90% | Upgrade
|
| Operating Margin | 4.20% | 10.36% | -17.85% | -3.08% | -0.36% | -97.56% | Upgrade
|
| Profit Margin | 6.75% | -0.23% | -13.88% | 9.99% | -24.68% | -119.53% | Upgrade
|
| Free Cash Flow Margin | -17.22% | -24.32% | -12.36% | -24.80% | 1.70% | -37.41% | Upgrade
|
| EBITDA | 8.78 | 17.71 | -8.91 | -2.48 | -0.04 | -41.74 | Upgrade
|
| EBITDA Margin | 7.33% | 13.06% | -16.60% | -2.86% | -0.06% | -96.34% | Upgrade
|
| D&A For EBITDA | 3.75 | 3.66 | 0.67 | 0.19 | 0.19 | 0.53 | Upgrade
|
| EBIT | 5.03 | 14.05 | -9.58 | -2.67 | -0.23 | -42.27 | Upgrade
|
| EBIT Margin | 4.20% | 10.36% | -17.85% | -3.08% | -0.36% | -97.56% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.